Bristol-Myers Squibb (BMY) is expected to boast a "solid" Q2 in line with expectations on revenue and earnings ahead of what is expected to be a "pivotal" H2, RBC Capital Markets said in note Friday.
RBC noted a lack of "idiosyncrasies" in the company's Q2.
"It's encouraging to see Bristol-Myers Squibb continue to execute across the commercial portfolio," the note said.
Investors remain focused on H2, with ahead of anticipated milestones for its Milvexian anti-stroke and Cobenfy Alzheimer's candidates, the note said.
RBC had a sector perform rating, with a $60 price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments